Navigation Links
B-Line Medical(TM) and the Center for Medical Simulation Announce Partnership
Date:9/10/2007

vices. In addition, these solutions provide evaluation/reporting, annotation, user management, and scheduling functionality. Both of these products unequivocally lead the industry in innovation, ease of use, and market share, having been selected by 30% of all US medical schools and a growing number of hospitals and nursing programs.

Dr. Jeffrey Cooper, Executive Director of CMS, said "We are very excited to be working with B-Line Medical on this project. This is an opportunity to take our simulation activities to a new level that will benefit both simulation participants and faculty, allowing for significant performance efficiencies and ease-of-use advantages. B-Line's expertise in software development and extensive experience in developing and supporting simulation facilities make them a unique partner, which will be of great value to CMS moving forward."

For more information please visit B-Line Medical's website at: http://www.blinemedical.com

About B-Line Medical

B-Line Medical's SimCenter/SimCube solutions have been selected by top tier medical institutions as the most advanced, comprehensive and easiest to use solutions for managing clinical skills and simulation training centers. Through its sophisticated web-based architecture, the SimCenter and SimCube address the complex set of challenges associated with running standardized patient and simulation scenarios, including simultaneous monitoring of numerous locations, testing and assessment, capturing data from multiple simulators of varying types, immediate debrief of simulation participants, and realtime video annotation. These elements are bound together in simple, secure interfaces that provides aggregate reporting and streamlined facility administration, while ultimately maximizing resources and allowing faculty and staff to focus on student and curriculum development.

About the Center for Medical Simulation

The Ce
'/>"/>

SOURCE B-Line Medical
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine news :

1. Stanford Medical Center Implements The First Virtual Cardiac Ultrasound
2. Risk of allergy more to children staying in day care centers
3. Expose on eating disorders!! Scientists trace “brain’s eating control center pathway”
4. Apollo Hospital to collaborate with US cancer center to open new radiation therapy department
5. Osaka Medical Center study showed 70% of smokers couldn’t qui
6. Kalam To Lay Foundation Of Vellore Research Center
7. Free Treatment Center Established In Chennai
8. Analyzing Client-Centered Therapy.
9. New policy allows Britons to decide on treatment center
10. Turkey becoming epicenter for bird flu
11. Human Milk Center Caters To Premature Babies
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 2Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 3Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 7Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program 2Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program 3Mirixa Corporation Announces Key New Hires 12958 1Mirixa Corporation Announces Key New Hires 12958 2Landmark project to map genomics of complex ant systems 9188 1Landmark project to map genomics of complex ant systems 9188 2European Health Care Institutions Forced to Select Lower Priced Interventional Cardiology Devices 51202 1European Health Care Institutions Forced to Select Lower Priced Interventional Cardiology Devices 51202 2